{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-25-011357","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2025-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.616055+00:00","generated_at":"2026-05-17T21:51:44.334772+00:00","sec_items":["3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Alzamend Neuro issues 243,429 common shares on conversion of Series B Preferred (Jul 23-30, 2025)","bullets":["243,429 common shares issued upon conversion of ~564.76 shares of Series B Convertible Preferred Stock.","Total common outstanding as of July 30, 2025: 3,139,861 shares.","Issuance made in reliance on Section 4(a)(2) exemption from registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-25-011357","json":"https://secwatch.observer/filing/0001214659-25-011357.json","markdown":"https://secwatch.observer/filing/0001214659-25-011357.md","text":"https://secwatch.observer/filing/0001214659-25-011357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925011357/0001214659-25-011357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925011357/i812508k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:51:44.334772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}